Abiomed to Highlight Data Analysis Identifying Complex Clinical Profile of Patients Receiving Impella-Supported HRPCI at TCT Symposium
The seven studies include an analysis of the characteristics of PROTECT III patients that demonstrates how physicians are distinguishing which patients are high-risk and appropriate for Impella-supported HRPCI procedures.
- The seven studies include an analysis of the characteristics of PROTECT III patients that demonstrates how physicians are distinguishing which patients are high-risk and appropriate for Impella-supported HRPCI procedures.
- The data shows that 82.5 percent of patients have features in all three high-risk domains: comorbidities, complex coronary anatomy and adverse hemodynamics.
- It also demonstrates that 99.6 percent of patients have risk factors from two or more of the high-risk domains.
- Abiomed's World Connect TCT Symposium takes place on Tuesday, Oct. 24 between 11 a.m.–12 p.m. PDT on Level 2 in the Presentation Theater.